Evidence map›Paper›PMID 40955815›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Tracker Nanocatalyst for Screening of Intracellular Copper-Catalyzed Azide-Alkyne Cycloadditions.

Mónica Rodríguez-Segura, Francisco Javier López-Delgado, María Victoria Cano-Cortés, Antonio Delgado-González, Juan Jose Diaz-Mochon, Rosario Maria Sanchez-Martin

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mónica Rodríguez-SeguraDepartment of Medicinal and Organic Chemistry, Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, School of Pharmacy, University of Granada, Campus Cartuja s/n, Granada, 18071, Spain.ORCID 0000-0002-6968-1786
Francisco Javier López-DelgadoDESTINA Genómica S.L, PTS Granada, Avenida de la Innovación 1, Edificio BIC, Armilla, 18100, Spain.ORCID 0000-0002-6968-5672
María Victoria Cano-CortésDepartment of Medicinal and Organic Chemistry, Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, School of Pharmacy, University of Granada, Campus Cartuja s/n, Granada, 18071, Spain.ORCID 0000-0003-1508-5476
Antonio Delgado-GonzálezDepartment of Medicinal and Organic Chemistry, Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, School of Pharmacy, University of Granada, Campus Cartuja s/n, Granada, 18071, Spain.ORCID 0000-0002-4760-8174
Juan Jose Diaz-MochonDepartment of Medicinal and Organic Chemistry, Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, School of Pharmacy, University of Granada, Campus Cartuja s/n, Granada, 18071, Spain.ORCID 0000-0002-3599-1954
Rosario Maria Sanchez-MartinDepartment of Medicinal and Organic Chemistry, Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, School of Pharmacy, University of Granada, Campus Cartuja s/n, Granada, 18071, Spain.ORCID 0000-0001-8912-9799

Funding

Andalusian Regional Government POSTDOC_21_00118Consejería de Salud y Consumo PIP-0232-2021Consejería de Salud y Consumo PIP-0245-2024European Union Next Generation EU/PRTR PDC2022.133913.I00European Union Next Generation EU/PRTR PID2022-141065OB-I00European Union Next Generation EU/PRTR RED2022-134560-TGENYO Centre for Genomics and Oncological ResearchPfizerStructural Analysis and Determination
6 · The paper itself

Abstract

Intracellular copper-catalyzed azide-alkyne cycloaddition (CuAAC) offers immense potential for bioorthogonal chemistry, but its application is severely hindered by copper toxicity and the challenge of controlling catalysis within the complex cellular environment. Heterogeneous copper catalysts can reduce toxicity by minimizing free copper exposure and enabling localized activity, yet optimizing their performance in situ within living cells remains a significant hurdle. Here, the development of a novel dual-functional nanocatalyst, Cu@BTTAA-Cy5-NPs, that combines robust heterogeneous CuAAC catalytic activity with intrinsic fluorescence tracking is reported. The successful synthesis and characterization of these monodispersed nanoparticles is demonstrated, confirming efficient copper loading stabilized by BTTAA and the nanoparticle matrix, and critically, the retention of Cy5 fluorescence for tracking. This unique dual functionality allows for real-time monitoring of nanoparticle localization and correlation with catalytic product formation via distinct fluorescence channels, enabling, for the first time to our knowledge, comprehensive in situ screening and optimization of CuAAC reaction conditions directly within living cells using fluorescence feedback. The nanoparticles exhibit excellent biocompatibility and cellular uptake, showing no significant toxicity, apoptosis, or oxidative stress at active concentrations.

Indexed as

AlkynesAzidesCopperCycloaddition ReactionNanoparticlesCatalysisHumansAlkynesAzidesCopperclick chemistryCuAAC reactionsheterogeneous copper nanocatalystsintracellular catalysisnano‐tracker

Identifiers

PMID40955815
PMCPMC12571216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.